Altos Labs Acquires Dorian Therapeutics
May 23, 2025
Altos Labs has acquired Stanford spinout Dorian Therapeutics, a preclinical senotherapeutics startup developing small-molecule "senoblockers." Financial terms were not disclosed; Altos said the deal broadens its cellular rejuvenation capabilities by adding Dorian’s epigenetic senescence-targeting technology and preclinical programs in lung fibrosis and osteoarthritis.
- Buyers
- Altos Labs
- Targets
- Dorian Therapeutics
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.